Literature DB >> 12967475

Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.

Yoshitomo Maesako1, Takashi Uchiyama, Hitoshi Ohno.   

Abstract

To determine the specific gene expression in B-cell lymphoma subtypes, we compared expression profiles of cell lines from transformed follicular lymphoma (tFL), Epstein-Barr virus-negative (EBV(-)) Burkitt's lymphoma (BL) and EBV(+)BL. Complementary DNAs were synthesized from these cell lines and hybridized with the Atlas Human 1.2 Array membrane. Hierarchical clustering analysis based upon the levels of 43 genes highlighted characteristic expression patterns of the 3 lymphoma subtypes. Genes expressed at higher levels in tFL than EBV(-)BL and EBV(+)BL included calcium/calmodulin-dependent protein kinase I (CAMK1) and mitogen-activated protein kinase 10 (MAPK10). EBV(-)BL was characterized by high-level expression of amyloid beta precursor protein (APP), heat shock 27 kD protein 1 (HSPB1) and mothers against decapentaplegic homolog 1 (MADH1). Gardner-Rasheed feline sarcoma viral oncogene homolog (FGR) was the most significant gene to delineate EBV(+)BL. A subtype prediction algorithm using 34 genes correctly classified 22 (92%) of 24 lymphomas into FL/tFL, EBV(-)BL or EBV(+)BL. By comparison with normal reference B-cell materials, the expression patterns of the selected genes were characteristic of lymphomas. We extended the clustering analysis to cell lines from de novo diffuse large B-cell lymphoma (DLBCL). The DLBCL cell lines were either separated from the former 3 lymphoma subtypes or segregated with EBV(+)BL, possibly reflecting variable genetic abnormalities. The associations of CAMK1 with tFL, APP and MADH1 with EBV(-)BL, FGR with EBV(+)BL, and BCL2 with tFL and DLBCL were confirmed by real-time quantitative reverse transcriptase-mediated polymerase chain reaction assays. This study has provided new molecular markers, expressions of which are closely associated with B-cell lymphoma subtypes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967475     DOI: 10.1111/j.1349-7006.2003.tb01518.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.

Authors:  Mette Ø Agerbaek; Marina A Pereira; Thomas M Clausen; Caroline Pehrson; Htoo Zarni Oo; Charlotte Spliid; Jamie R Rich; Vincent Fung; Francis Nkrumah; Janet Neequaye; Robert J Biggar; Steven J Reynolds; Giovanna Tosato; Sheeja T Pullarkat; Leona W Ayers; Thor G Theander; Mads Daugaard; Kishor Bhatia; Morten A Nielsen; Sam M Mbulaiteye; Ali Salanti
Journal:  Int J Cancer       Date:  2017-02-06       Impact factor: 7.396

2.  Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.

Authors:  Claudia D Baldus; Sandya Liyanarachchi; Krzysztof Mrózek; Herbert Auer; Stephan M Tanner; Martin Guimond; Amy S Ruppert; Nehad Mohamed; Ramana V Davuluri; Michael A Caligiuri; Clara D Bloomfield; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-08       Impact factor: 11.205

3.  Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

Authors:  Yibin Yang; Roland Schmitz; Joseph Mitala; Amanda Whiting; Wenming Xiao; Michele Ceribelli; George W Wright; Hong Zhao; Yandan Yang; Weihong Xu; Andreas Rosenwald; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Adrian Wiestner; Michael J Kruhlak; Kazuhiro Iwai; Federico Bernal; Louis M Staudt
Journal:  Cancer Discov       Date:  2014-02-03       Impact factor: 39.397

4.  Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.

Authors:  Fumiya Moribe; Momoko Nishikori; Tsuyoshi Takashima; Daiki Taniyama; Nobuyuki Onishi; Hiroshi Arima; Hiroyuki Sasanuma; Remi Akagawa; Fathi Elloumi; Shunichi Takeda; Yves Pommier; Eiichi Morii; Akifumi Takaori-Kondo; Junko Murai
Journal:  PLoS One       Date:  2021-01-29       Impact factor: 3.240

Review 5.  Transforming Growth Factor-Beta Orchestrates Tumour and Bystander Cells in B-Cell Non-Hodgkin Lymphoma.

Authors:  Matthew A Timmins; Ingo Ringshausen
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

6.  Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas.

Authors:  Ricardo Rivera-Soto; Yi Yu; Dirk P Dittmer; Blossom Damania
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

Review 7.  Amyloid precursor protein and amyloid precursor-like protein 2 in cancer.

Authors:  Poomy Pandey; Bailee Sliker; Haley L Peters; Amit Tuli; Jonathan Herskovitz; Kaitlin Smits; Abhilasha Purohit; Rakesh K Singh; Jixin Dong; Surinder K Batra; Donald W Coulter; Joyce C Solheim
Journal:  Oncotarget       Date:  2016-04-12

8.  An MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferation.

Authors:  Philipp Raffeiner; Jonathan R Hart; Daniel García-Caballero; Liron Bar-Peled; Marc S Weinberg; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-10       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.